Planet earth seen from space with clouds and landmasses

Does WHO Recommend Weight Loss Drugs?

The WHO's first global GLP-1 obesity guideline makes two conditional recommendations on moderate-to-low certainty evidence. Who it covers, and who it does not.

Fewer than 10% of those who could benefit from GLP-1 are projected to have access by 2030

In December 2025 the World Health Organization issued its first global guideline on GLP-1 weight-loss medicines for adults: two conditional recommendations that these drugs “may be used” as long-term treatment and that intensive behavioural therapy may be provided alongside them, on moderate-to-low certainty evidence, for adults over 19 living with obesity and not in pregnancy.

What this means

In December 2025 the World Health Organization issued its first global guideline on GLP-1 medicines for adult obesity. It makes two conditional recommendations — that GLP-1 receptor agonists or GIP/GLP-1 dual agonists “may be used” as long-term treatment in adults over 19 living with obesity, and that intensive behavioural therapy may be provided alongside them. The evidence behind them is graded moderate for the first and low for the second, because long-term data are limited and cost and access are unresolved. The boundary: the guideline covers adults with a body-mass index of 30 or above, excludes pregnancy, is not guidance for children and adolescents, and projects that fewer than 10% of those who could benefit will have access by 2030. Nothing here is a reason to start, stop or change a medication.

What the WHO actually recommends

In December 2025 the World Health Organization issued its first global guideline on GLP-1 therapies for adult obesity. It makes two recommendations, and both are conditional.

The first says that in adults living with obesity, GLP-1 receptor agonists or GIP/GLP-1 dual agonists “may be used” as a long-term treatment for obesity. The second says that in adults living with obesity who are prescribed those medicines, intensive behavioural therapy (IBT) “may be provided” as a co-intervention within a comprehensive multimodal clinical algorithm — that is, alongside the medicines, not instead of them.

Neither is a strong recommendation, and that distinction is the heart of the story. In WHO’s grading, a conditional recommendation means the desirable consequences do not clearly outweigh the undesirable ones from patient, clinical and public-health perspectives. The first recommendation rests on moderate certainty evidence; the second, on low certainty evidence. There are no strong recommendations in the guideline.

The guideline was developed with GRADE methods and published online on 1 December 2025. The JAMA article that carries it into the peer-reviewed record is a citable summary of it — first published online the same day, and printed in JAMA’s 3 February 2026 issue. Coverage that framed the guideline as newly issued in February 2026 has the date wrong: the guideline itself launched on 1 December 2025.

Why the two recommendations are conditional

The WHO names several reasons the evidence does not support a stronger call. Long-term efficacy and safety data are limited; how to start, maintain and stop treatment is not settled; current cost is high; health systems are not fully prepared; and access has equity implications. Patients also vary in what they prioritise, and what is feasible depends on the setting.

“Long-term” here means continuous use for 6 months or longer, following the current regulatory definition. The trials behind the guideline had follow-up of 6 to under 24 months, and of 24 months or more; data on maintenance and discontinuation remain limited. That is also why the guideline is written as a living document — one designed to be updated as evidence emerges, rather than fixed at first publication.

Three agents were evaluated and named: the GLP-1 receptor agonists liraglutide and semaglutide, and the GIP/GLP-1 dual agonist tirzepatide.

Who the guideline covers — and who it leaves out

The treatment recommendation is for adults older than 19 living with obesity, defined as a body-mass index (BMI) of 30 kg/m2 or higher. Pregnant women are excluded. Children and adolescents are not covered at all: a separate WHO guideline for their clinical management is under development. The guideline has a global scope, written for health systems across all income levels and capacities.

The access problem written into the guideline

WHO projects that even with rapid expansion in production, GLP-1 therapies will reach fewer than 10% of those who could benefit by 2030. The guideline calls for fair access, pooled procurement, tiered pricing and voluntary licensing, and says implementation depends on equitable access, health-system readiness and non-discriminatory care.

The scale it is meant to address is large. Obesity affects more than 1 billion people. Obesity-related non-communicable diseases accounted for 3.7 million deaths in 2024 — 12% of all NCD deaths — and global costs are predicted at US$3 trillion a year by 2030. The burden is projected to rise to 2 billion people by 2050; that is the corrected figure, after JAMA amended this article on 22 December 2025 to fix the projected year, which had been given as 2030.

Monitoring, not a green light

The guideline puts its safety framing in the same breath as the recommendation. It emphasises personalised, periodic monitoring of treatment response and of side effects and adverse events within obesity chronic-care programmes, and says health systems may consider prioritising people at higher risk of morbidity or mortality while ensuring health equity.

A living guideline, and the critiques it has drawn

Within months of publication, JAMA carried three letters in April 2026 and an author reply — a sign that the question is still moving rather than settled.

Redmond argued that obesity-associated cancer risk should be explicitly recognised in the guideline’s prioritisation framework. Dellepiane, Fadda and Mercado argued that a recommendation implying indefinite or lifelong treatment lacks long-term support, noting that the STEP and SURMOUNT trials supply only one to two years of data; they raised safety beyond two years, cost sustainability and weight regain after discontinuation. Fallahzadeh, Lentine and Singh argued that the “highest need” prioritisation framework should explicitly include solid-organ transplant candidates and recipients.

In their reply, the guideline authors accepted that cancer-related outcomes and other domains — such as cognition and addiction — are important for future updates. They noted that non-communicable diseases were not explicitly enumerated in the guideline, but that WHO recognises the links between obesity and cancer.

What happened next

On 30 July 2026, a joint WHO statement from its advisory committees on medicines and vaccines reaffirmed the conditional recommendation and warned about unregulated supply and off-label use, urging supervision by qualified health-care professionals. It is a later WHO record; it does not supersede the recommendation or change its strength.

What this is — and what it is not

This is what WHO recommends. It is not new evidence that the medicines work: the guideline is an authoritative, evidence-synthesising record built from systematic reviews and a network meta-analysis, not a clinical trial, and it reports no pooled effect sizes of its own. Its three named agents are not the whole field — a newer oral GLP-1 agent, orforglipron, has been tested in a large randomised trial — and parallel US and multi-society guidelines have appeared. The evidence base is still expanding, which is why the guideline is built to be updated.

It is also not guidance for pregnancy, or for children and adolescents. And nothing here is a reason for anyone to start, stop or change a prescription medicine; that decision belongs with a clinician.

Related coverage: our explainer on what happens when people stop weight-loss medications (what-happens-when-people-stop-weight-loss-medications) covers the discontinuation question, and our brief on whether GLP-1 drugs lower cancer risk (do-weight-loss-drugs-lower-cancer-risk) covers the cancer question raised in the letters. A Nutritious News piece on maintenance after stopping (post 3387) sits alongside them.

Terms explained

  • GLP-1 receptor agonist: a medicine that mimics GLP-1, a gut hormone involved in appetite and blood-sugar control. The guideline evaluated two of them, liraglutide and semaglutide.
  • GIP/GLP-1 dual agonist: a medicine that acts on two gut-hormone pathways rather than one. The guideline evaluated one, tirzepatide.
  • Conditional recommendation: a grading category meaning the desirable effects of an option probably outweigh the undesirable ones but do not clearly do so — so it is offered as “may be used”, not as a strong recommendation for everyone. Both of the WHO’s recommendations here are conditional.
  • Certainty of evidence (GRADE): a rating of how confident a guideline panel is in the evidence behind a recommendation, from very low to high. The WHO graded the first recommendation moderate and the second low.
  • Intensive behavioural therapy (IBT): a structured programme of diet, activity and behavioural support delivered as an add-on — here, as a co-intervention alongside the medicines, not a replacement for them.
  • Living guideline: a guideline written to be updated as new evidence emerges, rather than fixed at first publication. The WHO states this one will be updated regularly.

Keep reading on Nutritious News: Is Tirzepatide Better Than Semaglutide for Weight Loss?.

Sources

  1. Primary source: Celletti F, Farrar J, De Regil L. “World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.” JAMA 2026;335(5):434-438; first published online December 1, 2025. DOI: 10.1001/jama.2025.24288 · PMID: 41324410. Corrected December 22, 2025.
  2. Underlying guideline document: WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults (Guideline ID 4370, published 1 December 2025), hosted on MAGICapp: app.magicapp.org/#/guideline/LrRxrL.
  3. WHO news release: “WHO issues global guideline on the use of GLP-1 medicines in treating obesity,” 1 December 2025 (who.int).
  4. Subsequent WHO statement: WHO ACSoMP/GACVS joint statement on the safe and appropriate use of GLP-1 receptor agonists, 30 July 2026 (who.int).
  5. Comment letter: Redmond P. JAMA 2026;335(16):1449-1450. DOI: 10.1001/jama.2026.0681 · PMID: 41885806.
  6. Comment letter: Dellepiane D, Fadda M, Mercado DO. JAMA 2026;335(16):1451. DOI: 10.1001/jama.2026.0684 · PMID: 41885807.
  7. Comment letter: Fallahzadeh MK, Lentine K, Singh N. JAMA 2026;335(16):1450-1451. DOI: 10.1001/jama.2026.0678 · PMID: 41885811.
  8. Author reply: Celletti F, Farrar J, De Regil L. JAMA 2026;335(16):1451-1452. DOI: 10.1001/jama.2026.0687 · PMID: 41885820.
  9. Landscape — parallel professional guidance: “8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026.” Diabetes Care 2026;49:S166-S182. DOI: 10.2337/dc26-S008 · PMID: 41358882.
  10. Landscape — later multi-society guidance: 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. JACC 2026;87:e1889-e2007. DOI: 10.1016/j.jacc.2026.03.056 · PMID: 42265997.
  11. Landscape — new agent: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment” (ATTAIN-1). N Engl J Med 2025;393(18):1796-1806. DOI: 10.1056/NEJMoa2511774 · PMID: 40960239.

Related Articles